Physician profile
Kumar R Patel
NPI 1720198393
$123,908.73
in general payments reported to CMS, 2019-2025
32 companies · $12K in 2025
The $12K reported for 2025 was more than what 89% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,255 · 2020: $12K · 2021: $43K · 2022: $16K · 2023: $33K · 2024: $4,439 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $15K · Consulting Fee: $5,125 · Travel and Lodging: $2,259 · Education: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,650.00 |
| Food and Beverage | $14,632.92 |
| Consulting Fee | $5,125.00 |
| Travel and Lodging | $2,259.39 |
| Education | $295.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $91,918.10 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Novartis Pharmaceuticals Corporation | $7,789.08 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $6,518.51 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Optinose US, INC. | $4,386.75 | 2019-2025 | |
| Genzyme Corporation | $2,508.90 | 2019-2025 | |
| Csl Behring | $1,825.87 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Regeneron Healthcare Solutions, INC. | $1,689.85 | 2019-2025 | Dupixent |
| Amgen INC. | $1,041.58 | 2021-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $800.61 | 2019-2023 | |
| Genentech USA, INC. | $754.94 | 2019-2025 | Xolair |
| Biocryst US Sales Co., LLC | $693.46 | 2021-2025 | Orladeyo |
| Ars Pharmaceuticals Operations, INC. | $565.88 | 2025 | Neffy |
| Kaleo, INC. | $524.86 | 2019-2024 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $498.08 | 2019-2023 | Spiriva Respimat |
| Pfizer INC. | $404.71 | 2019-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $374.57 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $357.96 | 2021-2025 | Takhzyro, Eohilia |
| Grifols USA, LLC | $281.74 | 2023-2024 | Prolastin-C Liquid, Xembify |
| Incyte Corporation | $164.22 | 2024 | Opzelura |
| Horizon Therapeutics Plc | $152.25 | 2019-2021 | |
| Blueprint Medicines Corporation | $151.20 | 2024-2025 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $129.98 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $94.54 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $70.55 | 2019-2023 | |
| Cycle Pharmaceuticals INC | $64.55 | 2025 | Sajazir |
| Alk-Abello, INC | $36.73 | 2019 | |
| Azurity Pharmaceuticals, INC. | $22.94 | 2025 | Alvesco |
| Mylan Specialty L.P. | $19.95 | 2020 | |
| Phathom Pharmaceuticals, INC. | $18.45 | 2025 | Voquezna |
| Novo Nordisk INC | $16.83 | 2025 | |
| Phadia US INC. | $15.91 | 2024 | Immunocap |
| Circassia INC. | $15.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.